Targeting CKM: A Drug-Compatible Approach for Muscle Disease Treatment

Target Name: CKM

NCBI ID: G1158

Content of Review Report on CKM Target / Biomarker

CKM

Targeting CKM: A Drug-Compatible Approach for Muscle Disease Treatment

Creatine kinase (CKM) is a protein that is involved in the process of muscle contraction. It is a key enzyme that regulates the rapid and slow muscle contractions that are essential for movement. CKM is composed of two isoforms, CK-MM and CK-MB, which are located in the sarcolemma of muscle cells. The primary function of CKM is to catalyze the conversion of ATP to ADP and Pi, which is essential for the production of muscle contraction force.

Drugs that target CKM have been identified as potential therapeutic agents for a variety of muscle-related conditions, including muscle dystrophy, myopathies, and myopathic diseases. The use of these drugs is based on the fact that CKM is a drug target and can be manipulated to induce muscle contraction or relax muscle contractions.

Targeting CKM: A Drug-Compatible Approach

CKM is a versatile enzyme that can be targeted by various drug molecules. One of the most common strategies to target CKM is to inhibit the activity of CKM isoforms that are involved in muscle contraction. This can be achieved by using small molecules, such as inhibitors of the ATPase activity of CKM isoforms, or by using antibodies that bind to and inhibit the activity of CKM.

Another approach to targeting CKM is to activate the activity of CKM isoforms that are involved in muscle relaxation. This can be achieved by using agents that increase the activity of CKM isoforms that are involved in protein synthesis and degradation.

CKM Biomarkers

CKM is also a potential biomarker for muscle disease, as its activity can be affected by a variety of factors, including muscle loading, fatigue, and disease. Therefore, the measurement of CKM activity can be used as a diagnostic tool for muscle diseases, as well as a target for therapeutic intervention.

CKM isoforms are different proteins that are produced from a single gene, but they have distinct differences in their activity and localization. For example, CK-MM is the isoform that is primarily involved in muscle contraction, while CK-MB is the isoform that is primarily involved in muscle relaxation.

In addition, CKM activity can be affected by various chemical modifications, such as phosphorylation and ubiquitination. These modifications can alter the activity of CKM isoforms and affect their localization and stability. Therefore, the measurement of these modifications can also be used as biomarkers for muscle disease.

Conclusion

In conclusion, CKM is a versatile protein that is involved in the process of muscle contraction. It is a potential drug target and can be used to treat a variety of muscle-related conditions. The use of small molecules and antibodies that target CKM isoforms can be an effective way to inhibit or activate CKM activity and improve muscle function. Additionally, CKM activity can be used as a biomarker for muscle disease, which can be used to identify and diagnose muscle disorders.

Protein Name: Creatine Kinase, M-type

Functions: Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa

The "CKM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets